DT-Web

DB01607 - Ticarcillin


Identification
Name Ticarcillin
Accession Number DB01607
Type small molecule
Description An antibiotic derived from penicillin similar to carbenicillin in action.
Structure
MOL SDF PDB SMILES InChI
Categories (*)
Molecular Weight 384.427
Groups approved
Monoisotopic Weight 384.044977634
Pharmacology
Indication For the treatment of bacterial infections.
Mechanism of action Ticarcillin's antibiotic properties arise from its ability to prevent cross-linking of peptidoglycan during cell wall synthesis when the bacteria tries to divide, causing death.
Absorption Not Available
Protein binding 45%
Biotransformation Not Available
Route of elimination Not Available
Toxicity As with other penicillins, neurotoxic reactions may arise when very high doses of ticarcillin are administered, especially in patients with impaired renal function.
Affected organisms
  • Enteric bacteria and other eubacteria
Interactions
Drug Interactions
Drug Mechanism of interaction
Amikacin Ticarcillin may reduce the serum concentration of Amikacin. Ticarcillin may inactivate Amikacin in vitro and the two agents should not be administered simultaneously through the same IV line.
Demeclocycline Demeclocycline may reduce the effect of Ticarcillin by inhibiting bacterial growth. Ticarcillin exerts its effects on actively growing bacteria. To achieve synergism, Ticarcillin should be administered at least 2 hours prior to using Demeclocycline.
Doxycycline Doxycycline may reduce the effect of Ticarcillin by inhibiting bacterial growth. Ticarcillin exerts its effects on actively growing bacteria. To achieve synergism, Ticarcillin should be administered at least 2 hours prior to using Doxycycline.
Ethinyl Estradiol This anti-infectious agent could decrease the effect of the oral contraceptive
Fusidic Acid Fusidic acid may reduce the effect of Ticarcillin by inhibiting bacterial growth. Ticarcillin exerts its effects on actively growing bacteria. To achieve synergism, Ticarcillin should be administered at least 2 hours prior to using Fusidic acid.
Gentamicin Ticarcillin may reduce the serum concentration of Gentamicin. Ticarcillin may inactivate Gentamicin in vitro and the two agents should not be administered simultaneously through the same IV line.
Kanamycin Ticarcillin may reduce the serum concentration of Kanamycin. Ticarcillin may inactivate Kanamycin in vitro and the two agents should not be administered simultaneously through the same IV line.
Methotrexate The penicillin increases the effect and toxicity of methotrexate
Minocycline Minocycline may reduce the effect of Ticarcillin by inhibiting bacterial growth. Ticarcillin exerts its effects on actively growing bacteria. To achieve synergism, Ticarcillin should be administered at least 2 hours prior to using Minocycline.
Neomycin Ticarcillin may reduce the serum concentration of Neomycin. Ticarcillin may inactivate Neomycin in vitro and the two agents should not be administered simultaneously through the same IV line.
Oxytetracycline Oxytetracycline may reduce the effect of Ticarcillin by inhibiting bacterial growth. Ticarcillin exerts its effects on actively growing bacteria. To achieve synergism, Ticarcillin should be administered at least 2 hours prior to using Oxytetracycline.
Streptomycin Ticarcillin may reduce the serum concentration of Streptomycin. Ticarcillin may inactivate Streptomycin in vitro and the two agents should not be administered simultaneously through the same IV line.
Tetracycline Tetracycline may reduce the effect of Ticarcillin by inhibiting bacterial growth. Ticarcillin exerts its effects on actively growing bacteria. To achieve synergism, Ticarcillin should be administered at least 2 hours prior to using Tetracycline.
Tobramycin Ticarcillin may reduce the serum concentration of Tobramycin. Ticarcillin may inactivate Tobramycin in vitro and the two agents should not be administered simultaneously through the same IV line.
Food Interactions Not Available

Targets


Penicillin binding protein 2a
Name Penicillin binding protein 2a
Gene Name mecA
Pharmacological action yes
Actions inhibitor
References
  • Chambers HF, Sachdeva M, Kennedy S: Binding affinity for penicillin-binding protein 2a correlates with in vivo activity of beta-lactam antibiotics against methicillin-resistant Staphylococcus aureus. J Infect Dis. 1990 Sep;162(3):705-10. - Pubmed
DTHybrid score 0.5764

Predictions


Id Partner name Gene Name Score
6184 D-alanyl-D-alanine carboxypeptidase dacC dacC 0.0712
543 Penicillin-binding protein 1B mrcB 0.0575
6186 Penicillin-binding protein 1B ponB 0.0575
6822 Penicillin-binding protein 1b pbp1b 0.0575
6844 Penicillin-binding protein 1b pbp1b 0.0575
1 Peptidoglycan synthetase ftsI ftsI 0.0574
4155 Peptidoglycan synthetase ftsI ftsI 0.0574
645 Penicillin-binding protein 1A mrcA 0.0567
5805 Penicillin-binding protein 1A ponA 0.0567
6185 Penicillin-binding protein 1A mrcA 0.0567
6799 Penicillin-binding protein 1A pbpA 0.0567
1974 Oligopeptide transporter, kidney isoform SLC15A2 0.051
1539 Oligopeptide transporter, small intestine isoform SLC15A1 0.0485
633 Penicillin-binding proteins 1A/1B pbpA 0.0376
3760 Penicillin-binding protein 5 precursor dacA 0.0344
587 Serum albumin ALB 0.0316
118 Organic cation/carnitine transporter 2 SLC22A5 0.0273
↑